2331 GMT [Dow Jones]--Australian pharmaceutical company CSL's share price looks a good bet to outperform today, RBC Capital Markets says. CSL's FY26 underlying earnings and revenue beat expectations. "We think the market will particularly like the immunoglobulin performance with FY26 revenue growth of 4% year-over-year and 2H26 growth of 14% on-year," analyst Craig Wong-Pan says. CSL expects FY27 revenue to match the FY26 outcome. It also expects underlying profit growth of 5% when currency swings are stripped out. This implies an underlying net profit of US$2.93 billion, above consensus hopes of US$2.83 billion. "The stock has had a strong run into this result, however we expect the FY27 guidance beat to consensus and strong immunoglobulin performance in 2H26 to drive outperformance in the stock today," RBC says.